- Home
- SACH vs IOBT Comparison
SACH vs IOBT Comparison
Compare SACH & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SACH
- IOBT
- Stock Information
- Founded
- SACH 2010
- IOBT 2014
- Country
- SACH United States
- IOBT Denmark
- Employees
- SACH N/A
- IOBT N/A
- Industry
- SACH Real Estate Investment Trusts
- IOBT Biotechnology: Pharmaceutical Preparations
- Sector
- SACH Real Estate
- IOBT Health Care
- Exchange
- SACH Nasdaq
- IOBT Nasdaq
- Market Cap
- SACH 61.5M
- IOBT 56.7M
- IPO Year
- SACH 2017
- IOBT 2021
- Fundamental
- Price
- SACH $1.19
- IOBT $0.91
- Analyst Decision
- SACH Buy
- IOBT Strong Buy
- Analyst Count
- SACH 2
- IOBT 3
- Target Price
- SACH $2.25
- IOBT $9.33
- AVG Volume (30 Days)
- SACH 512.1K
- IOBT 320.5K
- Earning Date
- SACH 11-14-2024
- IOBT 11-12-2024
- Dividend Yield
- SACH 19.92%
- IOBT N/A
- EPS Growth
- SACH N/A
- IOBT N/A
- EPS
- SACH N/A
- IOBT N/A
- Revenue
- SACH $10,951,064.00
- IOBT N/A
- Revenue This Year
- SACH N/A
- IOBT N/A
- Revenue Next Year
- SACH N/A
- IOBT N/A
- P/E Ratio
- SACH N/A
- IOBT N/A
- Revenue Growth
- SACH N/A
- IOBT N/A
- 52 Week Low
- SACH $1.15
- IOBT $0.66
- 52 Week High
- SACH $4.64
- IOBT $2.10
- Technical
- Relative Strength Index (RSI)
- SACH 25.83
- IOBT 55.15
- Support Level
- SACH $1.15
- IOBT $0.75
- Resistance Level
- SACH $1.48
- IOBT $0.84
- Average True Range (ATR)
- SACH 0.07
- IOBT 0.06
- MACD
- SACH 0.01
- IOBT 0.02
- Stochastic Oscillator
- SACH 11.89
- IOBT 100.00
About SACH Sachem Capital Corp.
Sachem Capital Corp is a United States-based real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.